GH Research (GHRS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GHRS · Stock Price

USD 21.01+10.63 (+102.41%)

Market Cap: $1.4B

Historical price data

Market Cap: $1.4BPipeline: 8 drugsFounded: 2018HQ: Dublin, Ireland

Sector Ranking#162 in Small Molecule Drugs #23 in Neuroscience & CNS

Overview

GH Research is an Irish biotech company founded in 2018 with a mission to revolutionize the treatment of severe psychiatric disorders through its innovative mebufotenin-based platform. Its core achievement is the development of the Individualized Dosing Regimen (IDR), which has demonstrated high remission rates in early trials for treatment-resistant depression. The company's strategy is to advance its lead inhaled formulation, GH001, through late-stage clinical development for multiple indications, leveraging its strong intellectual property portfolio and aiming to address a massive unmet need with a potentially paradigm-shifting therapy.

PsychiatryNeurology

Technology Platform

Proprietary platform centered on mebufotenin (5-MeO-DMT), featuring multiple formulations (inhaled, IV, intranasal) and a patented Individualized Dosing Regimen (IDR) designed to induce rapid, durable remission in mood disorders with a single-day treatment paradigm.

Pipeline

8

8 drugs in pipeline

Drug	Indication	Stage
GH001	Postpartum Depression	Phase 2
GH001	Bipolar II Disorder	Phase 2
GH001 + Placebo	Treatment-resistant Depression	Phase 2
5 Methoxy N,N Dimethyltryptamine	Treatment Resistant Depression	Phase 1/2
5 Methoxy N,N Dimethyltryptamine + Placebo	Healthy Volunteers	Phase 1

Funding History

2

Total raised:$300M

IPO$175MUndisclosedJul 16, 2021

Series A$125MRA Capital ManagementMar 15, 2021

Opportunities

GH001 addresses a massive unmet need in multi-billion dollar markets (TRD, PPD, BDII) with a potential best-in-class profile: ultra-rapid remission within a single day and durable effects.

The streamlined treatment model, without mandated extensive psychotherapy, offers a significant scalability and cost advantage over other psychedelic-based approaches.

Risk Factors

High clinical trial risk as the company enters global Phase 3 development.

Regulatory pathway for a Schedule I psychedelic compound remains novel and uncertain.

Future capital needs for costly late-stage trials and potential commercialization are substantial, posing dilution risk.

Competitive Landscape

Competes against novel rapid-acting antidepressants (e.g., Spravato, Auvelity) and other psychedelic programs (e.g., Compass Pathways' psilocybin). Key differentiators are the ultra-short duration of mebufotenin's effect and the proprietary IDR protocol, which aims for high remission rates without the extensive psychotherapy model required by competitors.